ADELAIDE
bio news

In this issue

JAN - MARCH 2006

$35m investment for South Australian lifescience

The State's early stage bioscience companies are set to benefit from a new venture capital fund dedicated to life science.

Bio Innovation SA CEO, Dr Jurgen Michaelis, and MTAA Super Chairman, John Rickus, sign the MoU with Minister for Science and Information Economy, Karlene Maywald, and Premier, Mike Rann, looking on

Bio Innovation SA and the Motor Trades Association of Australia Superannuation Fund (MTAA Super) have finalised the establishment of the South Australian Life Science Venture Capital Fund, one of the largest venture capital funds in South Australia's history and the first of its kind in the country.

The Fund, to be managed by independent management company Terra Rossa Capital Pty Ltd, will invest exclusively in the biotechnology sector. It is anticipated that the fund will help the State's companies take their businesses to the next level of commercial success and assist in achieving the common goals of Bio Innovation SA and MTAA Super – to grow South Australia's bioscience industry.

The Chairman of Bio Innovation SA, Dennis Mutton said the MTAA Super investment was a clear vote of confidence in the State's bioscience community.

"We already have a world-class stable of outstanding companies led by commercially-focussed management in this State – this funding can ensure the next generation of industry leaders can step up onto the global stage."

MTAA Super's Adelaide-based Chairman John Rickus said that finalising the establishment of the Fund follows an exhaustive due diligence process on the State's biotechnology industry, its extensive research capabilities and also on Bio Innovation SA - the link that brings it all together.

"We have closely scrutinised the biotechnology industry in South Australia and its growth prospects, and we liked what we saw," Mr Rickus said.

"We recognised the significant investment potential in South Australia's biotechnology industry and were encouraged by the State Government's ongoing support of Bio Innovation SA and its outstanding work in fostering company growth."

Since Bio Innovation SA's establishment in 2001, the number of local biotechnology companies has doubled. There are now more than 70 biotechnology companies in SA, employing almost 1000 people and generating more than $175 million in revenue.

continued page 2…

BioInnovationSA

Bio Innovation SA
Level 15/33 King William Street
Adelaide South Australia 5000

Telephone 61 8 8217 6400
Facsimile 61 8 8217 6416
Email info@bioinnovationsa.com.au

Publication of Bio Innovation SA
An initiative of the Government of South Australia

Government of South Australia

…continued from page 1

Dr Jurgen Michaelis, Chief Executive of Bio Innovation SA said that investment by one of Australia's most successful superannuation funds into the local bioscience industry clearly demonstrates that Bio Innovation SA's strategy of promoting and fostering bioscience is paying off.

"This venture capital funding will provide a major boost to the local bioscience industry and provide long-term economic benefits to the State," said Dr Michaelis.

"Adelaide has one of the fastest-growing biotechnology industry clusters in Australia. I believe the outlook for the biotechnology industry is now brighter than ever and I anticipate a strong response to this new venture capital fund," Dr Michaelis said.

"Now the South Australian bioscience community has a local source of venture capital to help them grow."

Terra Rossa Capital will be fully operational within the coming months and is expected to make the first investment sometime this year.

Private, early stage South Australian bioscience companies or companies with a significant presence in South Australia are eligible for funding, with the amount available to companies assessed on a case-by-case basis.

For further information, visit
www.terrarossacapital.com
www.bioinnovationsa.com.au
www.mtaasuper.com.au

Capital Provider	Motor Trades Association of Australia Superannuation Fund (MTAA Super)
Commitments	MTAA Super: $35 million Bio Innovation SA: $1.9 million in grants to the manager to support its operations, and establishment of an 'Entrepreneur in Residence' Program
Term	15 years (comprising a 10 year investment period and a 5 year wind up period)
Type of Investment	Venture Capital
Name of Manager	Terra Rossa Capital Pty Ltd (Adelaide)
Individual Investments	In the range of $0.1 to $1.5 million
Industry Sector	Life Science, including medical (diagnostics, therapeutics, devices); agriculture (plant, wine, marine and animal biosciences); veterinary bioscience; environmental bioscience; biomaterials; healthcare products and technologies; other technologies with medical or biological applications.

The wheels are turning…

There are four elements that drive the growth of a bioscience industry: infrastructure, management, intellectual property and of course, all important money.

International experience has shown that the availability of infrastructure and equipment, international management expertise, intellectual property protection frameworks and ready access to finance at each stage of the development pipeline can result in a thriving bioscience sector.

Without one of these 'spokes' in this 'Wheel of Fortune', the capacity for industry growth is hindered…and can make for a bumpy ride!

This concept can be applied on a smaller plane – the elements that drive the growth of an industry would, of course, also drive the growth of an individual biotech company.

These four elements have played a strong part in determining Bio Innovation SA's strategy over the past years – we've recognised that by identifying needs and focussing our activities in these four areas, we can help strengthen the industry's capacity for growth. The Bioscience Business Incubator building is on its way, and will provide much-needed specialised infrastructure to the industry. The establishment of the $35 million Lifescience Venture Capital Fund will help to bridge the funding gap for many of our emerging companies and we will soon establish an Entrepreneur in Residence Program to provide companies with international management expertise. The new South Australian State Government Intellectual Property Policy will be adopted from July onwards to assist scientists in government research positions with commercialisation of their ideas and receiving inventor rewards.

These developments - highlighted in this edition - indicate that the four elements are not only in place, they are reinforcing the growth of the bioscience industry in South Australia.

Dr Jurgen Michaelis
Chief Executive
Bio Innovation SA

Management of people… attracting and retaining excellence

Dr Chris Goddard, Gropep Ltd's Chief Operating Officer

A chance meeting in the South of France brought Chris Goddard to Australia in 1994.

When Chris Goddard, now the Chief Operating Officer of GroPep Ltd, met the company's founder and then CEO Dr John Ballard in 1991, the weather came up in conversation.

"We were in the South of France, at a conference," explained Dr Goddard. "I was based in the UK at the time, working at the Roslin Institute in Edinburgh."

"I said 'It must be nice to work in a climate like this,' and John replied: 'You could if you wanted to.'"

Dr Ballard's research group – specialising in growth factors – was considered to be among the top three in the world.

The opportunity to work with the best people in his field was one that Chris Goddard did not want to miss.

"It was an opportunity to develop something of significance in a place that had so much to offer," he said.

"I had always wanted to apply my research and see it turned into products. I knew the relationship between John Ballard's research group and GroPep and recognised that moving to Adelaide would lead to great opportunities."

Those opportunities were personal as well as professional. Married, with three young children, Dr Goddard saw an opportunity to offer his family a better quality of life in Australia.

Today, he balances his career at GroPep with a passion for the "world game". He coaches his daughter's soccer team and is also involved in the sport at state level.

As a scientist, Dr Goddard started his career as a biochemistry student at Sheffield University in the UK.

He soon developed an interest in endocrinology and completed his PhD at St Bartholomew's Hospital in London – researching the adrenal cortex and how the body regulates steroid hormone production.

After conducting post-doctoral research at St Bartholomew's and the University of Manchester, he moved to Edinburgh to take up a position at the Roslin Institute, which hit the headlines worldwide for producing the first cloned mammal – Dolly the sheep.

"Some of my research into growth factors was linked to Dolly," he said. "But at Roslin I began to move out of the lab and into management. At first I was sceptical about management training but soon found that I enjoyed it immensely."

Today, Dr Goddard sees training programs and investment in people as central to a strategy that attracts and retains the best talent available, both nationally and internationally.

As Dr Goddard's experience attests, GroPep has had few problems attracting and retaining top international people. Four of the six people on GroPep's senior management team are from overseas.

"It's often said that people are the most important resource a company has but it's more than that. If you don't have the right mix of people, it won't work."

"You need a range of personalities and talents – you need the imaginative person; the person with financial and commercial sense; the excellent scientists; someone with commonsense and strong management and leadership skills. Then you have to work together as a team and trust each other."

For more information on GroPep Ltd, visit www.gropep.com.au

Protecting IP

Government agencies generate intellectual property through their ordinary business - and that can be a valuable State resource.

A SA Government Task Team, coordinated by Bio Innovation SA, has developed a new Intellectual Property Policy to provide a framework for the management of intellectual property within Government.

Dr Jurgen Michaelis, CEO of Bio Innovation SA and Chairman of the Task Team said the implementation of the Policy would bring benefits to both government and industry. "The Policy will raise the awareness of IP within Government organisations and encourage better management of IP across the public sector."

Dr Michaelis said a key element of the Policy is the mechanism whereby government chief executives can provide rewards to eligible inventors.

"It will also increase the capacity to capture opportunities from Government IP and foster the creation of start-up companies in areas that have a strong research link. It will contribute to the State's economic development, acting as a catalyst for establishing new industries," Dr Michaelis said.

The Policy will be implemented across all Government agencies from July 1st, 2006. Copies of the Policy can be downloaded from the Bio Innovation SA website at **www.bioinnovationsa.com.au.**

Building collaborative bioscience

The physical landscape of Adelaide's bioscience sector is changing, with a number of major collaborative infrastructure projects either underway or in the pipeline.

An artists impression of the Bioscience Business Incubator (Henn Architekten / JPE Capital Architecture)

The projects - spanning the spectrum from research and clinical facilities to start-up company incubation – involve a number of partner organisations who recognise the benefits of co-location and collaboration.

The Waite Precinct, long recognised as a hub for wine research, is the site of a collaboration that will materialise in the form of a purpose-built facility. The South Australian Government will contribute $9.5m over two years towards the Wine Innovation Cluster (WIC) building, which will house the Australian Wine Research Institute (AWRI), SARDI viticulture staff and University of Adelaide Wine and Horticulture scientists, with links to the CSIRO Plant Industry building.

Dr Sakkie Pretorius, Managing Director of the Australian Wine Research Institute said the aim of the collaboration was to maximise interaction between the different parties to deliver outcomes for the wine industry. "The 'vine to wine' research capability involves sharing of key infrastructure in the analytical, fermentation, sensory and metabolomics area," he said.

Another current capital works project designed to encourage collaboration and information flow is Bio Innovation SA's Bioscience Business Incubator, to be located at the Thebarton Bioscience Precinct.

Prof Gunter Henn, CEO of Henn Architekten and the designer of the Bioscience Business Incubator believes the flow of communication should be the foundation for any construction project – particularly in a scientific environment. In a recent interview with The Advertiser newspaper, Prof Henn said that it is thinking not only alone but thinking together that makes us successful.

"Before we had places; now it is a network of information flow. We have to look for nodes and make out of those nodes a centre of gravity."

"This Incubator will form a centre of gravity for the Thebarton Bioscience Precinct."

Scheduled to open in late 2007, the facility will provide either office only or office/laboratory modules along with business services and technical support for up to 16 early stage bioscience companies. Stage 2 of the Precinct will also offer land allotments for future development by biotechnology companies.

Bio Innovation SA is putting together a consortium of companies who are interested in developing a new multi-tenanted building at Thebarton. For further information contact Ann Nelson on at ann.nelsom@bioinnovationsa.com.au.

Other projects in the pipeline:

Centre for Innovation in Cancer

Fundraising for the $14.5m Centre for Innovation in Cancer, to be built at the Flinders Medical Centre received a boost in early March, following a $1m pledge from the Australian Cancer Research Foundation. The State Government has contributed $2.5m towards the multi-storey research complex, which will focus on cancer prevention and better delivery of cancer control techniques.

Florey Precinct

Work is progressing on developing a preliminary business case and master plan for a proposed Health and Medical Research Institute within the Florey Precinct in Adelaide's CBD. It is envisaged that the Health and Medical Research Institute will be recognised internationally for medical research and development, education and innovative health service delivery for intergenerational health.

Research Centre for Reproductive Health

A $5.5m refurbishment is underway at the University of Adelaide's Medical School South Building on Frome Road, Adelaide. With part funding from the State Government, the project includes the development of new laboratories and will allow for the re-location of the University's reproductive health researchers from the Queen Elizabeth Hospital to the University's city campus. The Research Centre for Reproductive Health will be co-located with the University's Department of Obstetrics and Gynaecology, consolidating the University's reproductive research capabilities.

Mawson Institute for Advanced Manufacturing

The State Government will provide $8m over the next 4 years to establish the Mawson Institute of Advanced Manufacturing on the Mawson Lakes campus of the University of South Australia. The Mawson Institute will conduct research in advanced manufacturing systems, product and process innovation and its integration into Australian manufacturing enterprises.

Adelaide Facilities

The Flinders Microscopy and Image Analysis Facility

The Flinders Microscopy and Image Analysis Facility (FMIAF) is a $3 million research facility known for its high resolution imaging from electron and confocal microscopes.

Prof Ian Gibbins and Ms Jennifer Clarke with the new Leica SP5 confocal microscope

Located at the Flinders Medical Centre, the facility now has a new $1m state-of-the-art Leica SP5 confocal microscope for imaging molecular interactions within cells and tissues.

The Leica SP5, which is the first of its kind in Australia, features the capacity to image five fluorescent markers simultaneously and perform the latest applications in fluorescence microscopy, making it one of the most advanced instruments of its kind.

"It opens up tremendous possibilities for researchers from academia and industry," said Jennifer Clarke, the FMIAF confocal microscope facility manager.

"With the right fluorescent markers, important molecular interactions can be studied in real-time in living cells."

Equipped with an environmental stage controller for live cell studies, the microscope can be used, for example, to investigate how new drugs affect living cells.

"We are very keen to collaborate with and provide services to researchers in the bioscience community," said Ms Clarke. "We are also able to train people to use the microscope themselves."

Confocal microscopes use lasers of different wavelengths together with a series of optical detection devices and sophisticated precise computerised controls to perform high resolution imaging of cells and tissues labeled with fluorescent markers.

The laser optics is such that precise optical layers of a specimen can be viewed within living or fixed cells/tissues. Capturing a series of optical images enables 3D reconstruction of the specimen.

In living cells, the spatial interactions between labelled molecules and the rate of movement, diffusion, synthesis or degradation of molecules can also be measured.

The outstanding features of the Leica SP5 confocal microscope include the availability of 8 distinct laser lines (enabling the use of the full spectrum of fluorescent labels); 5 fully adjustable, simultaneous detection channels; and a dual channel Fluorescence Correlation Spectroscopy (FCS) capacity.

The recent technological advance of coupling FCS with high resolution confocal microscopy means it is now possible to detect the rates of binding and/or diffusion of different molecules by optical measurements within live cells.

The FMIAF is one of Bio Innovation SA's AIB Labs – a network of research facilities at key locations in South Australia, designed to meet the needs of the bioscience community.

For more information about the FMIAF and its Leica SP5 confocal microscope, contact Jennifer Clarke at jennifer.clarke@flinders.edu.au.

Manufacturing first for BresaGen

BresaGen Ltd will soon commission the first small scale aseptic vial filling service in South Australia.

Available for clinical trial and commercial non-cytotoxic, non-infectious products, the service will be offered to BresaGen's existing clients as well as new customers requiring non-protein product filling.

Chief Operating Officer Dr Meera Verma said the facility is a logical extension to BresaGen's existing services. "We can now offer our clients a complete service, including formulation development, validated sterility testing and batch release," Dr Verma said.

Purchased with the assistance of a Bio Innovation SA Commercial Infrastructure Grant, the filling line will also meet a market need. Sterile injectable products, including those for clinical trials, must be produced in a TGA*-approved facility licensed for aseptic filling. Only two interstate companies currently offer aseptic filling of biologicals in Australia, neither of which are set up to deal with small third party contracts.

"The service will be cost competitive and have the flexibility to fill small batch sizes as well as conduct larger batch manufacturing," Dr Verma said.

Installation of the filling line is expected to be complete by the end of May this year, with the service operational by June 2006.

For more information contact Dr Michael Egan, Business Development Manager via email at sales@bresagen.com.au

* Therapeutic Goods Administration

Wheat research to benefit industry

Dr Hugh Wallwork with Prof Diane Mather

Wheat quality research at the Waite Precinct may lead to greater yields and increased exports for SA's grain industry, following announcement of the Premier's Science and Research Fund recipients for 2005/06.

The project "Value-adding for the SA Wheat Industry" will receive $647,900 over 4 years and is being jointly managed through the Molecular Plant Breeding CRC by Dr Hugh Wallwork of the South Australian Research and Development Institute (SARDI) and Prof Diane Mather of the Plant and Pest Sciences Unit of the University of Adelaide (Waite Campus).

Dr Wallwork said the funding will go towards research that adds value, securing markets for the State's wheat exports. "It will also help foster collaborative research, ensuring the Waite Precinct retains its leading position in agricultural science and develops a stronger position in cereal chemistry and food science," he said.

The grains industry is a significant contributor to the SA economy, with exports worth $1.4b in 2003/04. Dr Wallwork says that South Australia's Strategic Plan aims to increase this figure to $3.9b per annum by 2012/13. "This target is particularly ambitious considering Australia is likely to lose market share for wheat due to increasing competition from production zones in the former Soviet republics," he said.

Dr Wallwork's and Prof Mather's project will look at ways to increase the area sown to durum wheat across the State, focussing on a major production impediment to durum wheat - its high susceptibility to crown rot. "This fungal disease has resulted in many durum crops failing to receive durum classification, leaving farmers the option to collect very low feed prices or simply cut their crops for hay. Only 10 years ago SA's durum industry was rapidly expanding, but crown rot has seen the area sown reduced by 50% over the past two years," Dr Wallwork said.

The Premier's Science and Research Fund will also support the project's investigation into genetically controlled traits that can be bred into wheat to enhance processing qualities, taste and health benefits of wheat products.

"In the future, health benefits may come from fortifying wheats with higher levels of iron and zinc, or through identifying wheat varieties with improved starch qualities - that in turn increases the absorption of these micronutrients during digestion. Removal of wheat gliadins may also help coeliacs, who are intolerant to current wheat varieties," Dr Wallwork said.

For further information on the project, contact Dr Hugh Wallwork at wallwork.hugh@saugov.sa.gov.au

New company to tap into European crop testing market

An offshoot of the world-renowned Australian Centre for Plant Functional Genomics (ACPFG) has been established to develop scientific techniques for genetic crop testing in Europe.

In collaboration with German company Lifeprint GmbH, the ACPFG has established Lifeprint Australia Pty Ltd, to be based at the ACPFG headquarters at the University of Adelaide's Waite Campus.

Lifeprint GmbH specialises in food DNA testing, particularly for genetic modification (GM) or potential allergens. Lifeprint Australia will develop new scientific testing techniques for Lifeprint GmbH, allowing both companies to capture the growing food testing market.

There is a strong market for GM testing in food crops, where food labelling laws in countries like Australia and Germany mean food producers need to be able to trace GM. More than 8 million farmers grow genetically modified crops in 21 countries, including Australia.

Prof Peter Langridge, a Director of Lifeprint Australia and CEO of the ACPFG, said he hopes better genetic testing technologies will increase consumer confidence in GM foods.

"The reality is that GM is a part of agriculture today. At the ACPFG we use these technologies in research and accept the associated responsibilities. It is important to give consumers as much information as possible and I hope that Lifeprint Australia will be able to help increase awareness and understanding of gene technologies," said Prof Langridge.


L-R: Mr Michael Gilbert, Dr Andrew Milligan, Prof Peter Langridge and Mr Stephen Fletcher of the ACPFG

Lifeprint was established in Germany by Drs Sibylle Roesel and Waltraud Böhm in 2001 and is based in Illertissen, near Ulm.

"Lifeprint is an innovative business that will be enhanced with the scientific resources of this new Australian company. I look forward to working with Australian scientists on new food testing techniques to meet European demand," said Dr Roesel, who is also a Director of Lifeprint Australia.

For further information contact: Belinda Barr (ACPFG) at belinda.barr@acpfg.com.au

Testing the waters

Researchers can now detect the presence of blue-green algae at the water's edge, thanks to DNA technology developed at SA Water's Australian Water Quality Centre (AWQC) at Bolivar.



A mobile detection device used in combination with the polymerase chain reaction (PCR) can identify toxic blue-green algae within hours, using DNA tags to spot toxin-producing genes.

SA Water's Research and Development Manager, Assoc Prof Chris Saint said the purpose of developing the test was to speed up the detection of problem-causing micro-organisms in South Australia's water reserves.

"This new technology provides results in as little as an hour, which is crucial when dealing with toxic cyanobacteria," Assoc Prof Saint said.

Blue-green algae threatens the safety and quality of drinking water supplies and can render affected sources unsuitable for agricultural purposes. Blue-green algal toxins are colourless, odourless, and can remain present in water for weeks after the blue-green algal bloom has disappeared.

Research Microbiologist Dr Paul Rasmussen is using the new device to detect the presence of very low levels of DNA from specific genes found in blue-green algae. In the past, researchers have detected the presence of the algae through microscopy, while toxins are detected using chemical analysis methods such as liquid chromatography and mass spectrometry. "This two-step process was time-consuming and expensive…sometimes results would show that the algae present were not producing toxins at all," Dr Rasmussen said. "This new method investigates whether the genes required for the production of toxins are present in the first place".

The mobility of the test, which is the size of a car battery and runs from a laptop computer, means that samples can be tested soon after they are collected, without degradation.

"This new method will not only help SA Water establish more flexible laboratories, it will result in time and cost savings and improved accuracy of water testing processes," Assoc Prof Saint said.

For more information contact: Michelle Bini at SA Water at michelle.bini@sawater.com.au

---

International Health Conference for Adelaide

South Australia is set to host an international health technology conference later this year.

Health Technology Assessment International (HTAi), an international society for the promotion of health technology assessment will hold its 3rd Annual International Meeting at the Adelaide Convention Centre in July.

The meeting will bring together researchers, clinicians, policy makers, and members of the healthcare industry to discuss the management of technological innovation and diffusion in the sector.

Prof Brendon Kearney, Director of the Institute of Medical and Veterinary Science and Chair of the meeting's local organising committee said that the development of new systems will be a focus of the program.

"Sharing of information on how to cope with increasing demand for these new health interventions will be a highlight of the meeting," said Prof Kearney.

The meeting program will also address methodologies that assess drugs, surgical procedures, devices and prostheses. Specific emphasis will be placed on approaches to the assessment of vaccines.

"We also intend to look at how systems can respond in situations where diffusion of technologies is unregulated," said Prof Kearney.

Prof Kearney said the meeting program would appeal to an international audience. "We will address issues of interest to delegates from North America and Europe, as well as those topical to the Asia Pacific region - in particular the contribution HTAi can make to emerging diseases in this region."

The Meeting will be held from the 2nd – 5th July 2006. Further information and registration details can be found at www.htai.org/australia-2006

Coming events

BIO 2006

Chicago, USA
9-12 April 2006
www.bio.org/events/2006

Australasian Plant Breeding Conference

Christchurch, New Zealand
18-21 April 2006
www.apbc.org.nz

BIO Equity Europe

22-23 May, 2006
Frankfurt, Germany
www.biocentury.com

Commercialisation Expo 2006

18-20 June 2006
Melbourne, Australia
www.expo2006.com.au

HTAi 2006

3rd Annual Meeting of Health Technology Assessment International
Adelaide, Australia
2-5 July 2006
www.htai.org/australia-2006

ASM 2006

Australian Society for Microbiology Annual Conference
Gold Coast, Australia
2-6 July 2006
www.asm2006.org

Communications consultant
Sharon Mascali
Making Sense Communications

In Brief

So far this financial year, Bio Innovation SA has provided $198,633 to five projects under its Commercial Development Initiative Scheme, $191,467 to seven companies applying for Business Development Initiative funding and $100,000 to two companies under its BioArc Scheme.

Starting in the next issue of Bionews, we will feature profiles of the technologies and companies funded under our grant programs.

For further information on Bio Innovation SA's grant funding, visit www.bioinnovationsa.com.au or call (+618) 8217 6400.

Congratulations

Congratulations to recipients of Flinders University's distinguished Alumni and Staff Awards, announced as part of the University's 40th Anniversary on 25 March 2006.

Farewell...

George Varkanis, the Commercial Director of Bio Innovation SA, has moved back to the pharmaceutical industry as General Manager of Celgene Australia. Celgene is a US-based biopharmaceutical company specialising in the development of treatments for cancer and inflammatory diseases.

...and welcome back!

Mr Neil Finlayson, former Business Development Director at Bio Innovation SA will return to his previous position in late April this year.

Neil returns to South Australia having spent two years as the Director of Commercialisation at Griffith University in Queensland. Neil says he is looking forward to rejoining the Bio Innovation SA team and renewing old friendships.

World Class Proteomics Centre Opens in Adelaide

The Adelaide Proteomics Centre is now open, offering world class, state-of-the-art research facilities to industry and academic institutions throughout the country.

Based at the University of Adelaide, the $3m Centre is the only one of its kind in South Australia. It was built and equipped with the support of the Australian Cancer Research Foundation, the Australian Research Council and Bio Innovation SA.

"We're already working with large, internationally recognised biotech companies based in the state," said Dr Peter Hoffmann, the director of the Centre. "We welcome collaboration with the bioscience community."

For more information about the Adelaide Proteomics Centre contact Dr Peter Hoffman at peter.hoffmann@adelaide.edu.au

People on the move

- Dr Anne Collins, Executive Director of Virient Pty Ltd has been appointed to the Chair of the SA Chapter of AusBiotech. Anne replaces Peter Bradley, who has joined New Zealand company KODE Biotech Ltd as CEO.
- Professor Grant Sutherland has been elected Chair of the Adelaide Integrated Bioscience Laboratories (AIB Labs) Steering Committee.
- Dr Atul Kacker replaces Dr Mavis Abbey as Centre Director for CSIRO Human Nutrition, following Dr Abbey's retirement.

- Ms Sarina Caruso, formerly of Bio Innovation SA has joined the University of South Australia's commercialisation company ITEK as Legal Counsel.
- Mr Alistair MacFarlane has moved from Adelaide Research and Innovation to Adelaide-based Merchant Bank, Beston Pacific as Corporate Executive.